I just came across an interesting dispute between YZi Labs and 10X Capital, highlighting the limits of U.S. disclosure obligations. It concerns whether 10X Capital has properly disclosed its stake in CEA Industries, better known as BNC.

The core issue: YZi Labs alleges that by exercising warrants until the end of 2025, 10X may have exceeded the critical 5% threshold in BNC — a limit that typically requires a 13D filing once crossed. So far, no such filing has been submitted. That’s no small matter, considering how important these transparency rules are for the market.

What makes the matter even more complicated: YZi Labs has also scrutinized the so-called "poison pill" strategy of the board and questions whether this, along with other coordinated measures, might constitute an undisclosed "group." If so, that would also fall under SEC reporting requirements.

The interesting part is that 10X Capital apparently tries to expand its influence here without adhering to the usual transparency rules. YZi Labs has therefore called on the SEC to demand immediate supplementary disclosures and to clarify these discrepancies. It’s a good reminder that even in established markets, such compliance issues keep arising, and investors and regulators must stay vigilant.